Seminars in Oncology
Volume 31, Issue 4 , Pages 465-475 , August 2004

Pathology of upper gastrointestinal malignancies

  • Mario Sarbia

      Affiliations

    • Institute of Pathology, Technische Universität München, München, Germany
    • Corresponding Author InformationAddress reprint requests to Mario Sarbia, MD, Institute of Pathology, Technische Universität München, Ismaninger Straβe 22, 81675 München, Germany
    • ,
  • Karl Friedrich Becker

      Affiliations

    • Institute of Pathology, Technische Universität München, München, Germany
    • ,
  • Heinz Höfler

      Affiliations

    • Institute of Pathology, Technische Universität München, München, Germany

References 

  1. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer. 1996;78:1820–1828
  2. Borrman R. Geschwülste des Magens und Duodenums. In:  Henke F,  Lubarsch O editor. Handbuch der Speziellen Pathologischen Anatomie und Histologien. Berlin, Germany: Springer Verlag; 1926;p. 864–871
  3. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  4. Fenoglio-Preiser C, Stemmermann GN, Lantz PE, et al.  Gastrointestinal Pathology. (ed 2). Philadelphia, PA: Lippincott-Raven; 1999;
  5. Siewert JR, Stein H. Classification of adenocarcinoma of the esophago-gastric junction. Br J Cancer. 1998;85:1457–1459
  6. Association of Directors of Anatomic and Surgical Pathology . Recommendations for the reporting of resected esophageal carcinomas. Virchows Arch. 2000;437:348–350
  7. World Health Organisation . In:  Hamilton SR,  Aaltonen LA editor. Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000;
  8. Japanese Research Society for Gastric Cancer . Japanese Classification of Gastric Carcinoma. 1st English Edition. Tokyo, Japan: Kanehara; 1995;
  9. Lewin KJ, Appelman HD. Atlas of Tumor Pathology (Tumors of the Esophagus and Stomach). Washington, DC: Armed Forces Institute of Pathology; 1996;
  10. Japanese Society for Esophageal Diseases . Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. (ed 9). Tokyo, Japan: Kanehara; 2001;
  11. Kuwano H. Peculiar histopathologic features of esophageal cancer. Jpn J Surg. 1998;28:573–575
  12. Sarbia M, Bittinger F, Porschen R, et al.  Prognostic value of histopathologic parameters of esophageal squamous cell carcinoma. Cancer. 1995;76:922–927
  13. Malik AB, Bidani JA, Rich HG, et al.  Long-term survival in a patient with verrucous carcinoma of the esophagus. Am J Gastroenterol. 1996;91:1031–1033
  14. Hanada M, Nakano K, Ii Y, et al.  Carcinosarcoma of the esophagus with osseous and cartilaginous production. Acta Pathol Jpn. 1984;34:669–678
  15. Sarbia M, Verreet P, Bittinger F, et al.  Basaloid squamous cell carcinoma of the esophagus. Cancer. 1997;79:1871–1878
  16. Lauren P. The two histological main types of gastric carcinoma (Diffuse and so-called intestinal-type carcinoma). Acta Path Microbiol Scand. 1965;64:31–49
  17. Kalish RJ, Clancy PE, Orringer MB, et al.  Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and in the gastric cardia. Gastroenterology. 1984;86:461–467
  18. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas (Recent changes in type and frequency). Hum Pathol. 1986;17:482–487
  19. Ide H, Nakamura T, Hayashi K, et al.  Esophageal squamous cell carcinoma (Pathology and prognosis). World J Surg. 1994;18:321–330
  20. Natsugoe S, Mueller J, Stein HJ, et al.  Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma. Cancer. 1998;83:858–866
  21. Akiyama H, Tsurumaru M, Udagawa H, et al.  Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–373
  22. Monig SP, Baldus SE, Zirbes TK, et al.  Topographical distribution of lymph node metastasis in adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology. 2002;49:419–422
  23. Maruyama K, Gunven P, Okabayashi K, et al.  Lymph node metastases of gastric cancer. General pattern in 1932 patients. Ann Surg. 1989;210:596–602
  24. Ishida K, Katsumara T, Sugiyama A, et al.  Immunohistochemical evaluation of lymph node micrometastases from gastric carcinoma. Cancer. 1997;15:1069–1076
  25. Gabbert HE, Meier S, Gerharz CD, et al.  Incidence and prognostic significance of vascular invasion in 529 gastric-cancer patients. Int J Cancer. 1991;49:203–207
  26. Sarbia M, Porschen R, Borchard F, et al.  Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinoma of the esophagus. Int J Cancer. 1995;61:333–336
  27. Kato H, Tachimori Y, Watanabe H, et al.  Evaluation of the new (1987) TNM classification for thoracic esophageal tumors. Int J Cancer. 1993;53:220–223
  28. Katai H, Yoshimura K, Maruyama K, et al.  Evaluation of the new International Union Against Cancer TNM staging for gastric cancer. Cancer. 2000;88:1763–1765
  29. Hermanek P. Tumor of the gastrointestinal tract and the pancreas (Histopathology, staging, and prognosis). Anticancer Res. 1999;19:2393–2396
  30. UICC . In:  Sobin LH,  Wittekind C editor. TNM Classification of Malignant Tumours. (ed 6). New York, NY: Wiley; 2002;
  31. Poon RTP, Law SYK, Chu KM, et al.  Multiple primary cancers in esophageal squamous cell carcinoma (Incidence and implications). Ann Thorac Surg. 1998;65:1529–1534
  32. Montgomery E, Bronner MP, Goldblum JR, et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus (A reaffirmation). Hum Pathol. 2001;32:368–378
  33. Schlemper RJ, Dawsey SM, Itabashi M, et al.  Differences in diagnostic criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists. Cancer. 2000;88:996–1006
  34. Willis J, Riddell RH. Biology versus terminology (East meets West in surgical pathology). Gastrointest Endosc. 2003;57:369–376
  35. Schlemper RJ, Riddell RH, Kato Y, et al.  The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255
  36. Dixon MF. Gastrointestinal epithelial neoplasia (Vienna revisited). Gut. 2002;51:130–131
  37. Dawsey SM, Lewin KJ, Wang GQ, et al.  Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. Cancer. 1994;74:1686–1692
  38. Practice Parameters Committee of the American College of Gastroenterology Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 1998;93:1028–1032
  39. Hirota WK, Loughney TM, Lazas DJ, et al.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction (Prevalence and clinical data). Gastroenterology. 1999;116:277–285
  40. Lagergren J, Bergström R, Lindgren A, et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  41. Wijnhoven BPL, Siersma PD, Hop WCJ, et al.  Adenocarcinoma of the distal esophagus and gastric cardia are one clinical entity. Br J Surg. 1999;86:529–535
  42. Ruol A, Parenti A, Zaninotto G, et al.  Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer. 2000;88:2520–2528
  43. Huang JQ, Sridhar S, Chen Y, et al.  Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–1179
  44. Werner M, Becker KF, Keller G, et al.  Gastric adenocarcinoma (Pathomorphology and molecular pathology). J Cancer Res Clin Oncol. 2001;127:207–216
  45. Filipe MI, Munoz N, Matko I, et al.  Intestinal metaplasia types and the risk of gastric cancer (A cohort study in Slovenia). Int J Cancer. 1994;57:324–329
  46. Goldstein NS, Lewin KJ. Gastric epithelial dysplasia and adenoma (Historical review and histological criteria for grading). Hum Pathol. 1997;28:127–133
  47. Rugge M, Cassaro M, Di Mario F, et al.  The long term outcome of gastric non-invasive neoplasia. Gut. 2003;52:1111–1116
  48. Takubo K. Pathology of the Esophagus. Tokyo, Japan: EDUCA; 2000;
  49. Kusayanagi S, Konishi K, Miyasaka N, et al.  Primary small cell carcinoma of the stomach. J Gastroenterol Hepatol. 2003;18:743–747
  50. Shibuya H, Azumi N, Abe F. Gastric small-cell undifferentiated carcinoma with adeno and squamous cell carcinoma components. Acta Pathol Jpn. 1985;35:473–480
  51. Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Atlas of Tumor Pathology, 3rd series, fascicle 13. Washington, DC: Armed Forces Institute of Pathology; 1994;
  52. Rindi G, Bordi C, Rappel S, et al.  Gastric carcinoids and neuroendocrine carcinomas (Pathogenesis, pathology and behavior). World J Surg. 1996;20:168–172
  53. Lam AK. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2000;33:71–90
  54. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis (A review). Int J Cancer. 1996;69:225–235
  55. Walch AK, Zitzelsberger HF, Bruch J, et al.  Chromosomal imbalances in Barrett’s adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol. 2000;156:555–566
  56. Riegmann PHJ, Vissers KJ, Alers J, et al.  Genomic alterations in malignant transformation of Barrett’s esophagus. Cancer Res. 2001;61:3164–3170
  57. Sarbia M, Arjumand J, Wolter M, et al.  Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett’s esophagus. Am J Clin Pathol. 2001;115:835–840
  58. Bian YS, Osterheld MC, Fonolliet C, et al.  p16 inactivation by methylation of the CDKN2A promotor occurs early during neoplastic progression in Barrett’s esophagus. Gastroenterology. 2002;122:1113–1121
  59. Wong DJ, Paulson TG, Prevo LJ, et al.  p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplasic epithelium. Cancer Res. 2001;61:8284–8289
  60. Barrett MT, Sanchez CA, Galipea PC, et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barretts esophagus. Oncogene. 1996;13:1867–1873
  61. Hamelin R, Flejou JF, Muzeau F, et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology. 1994;107:1012–1018
  62. Schneider PM, Stoeltzing O, Roth JA, et al.  p53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinom in Barrett’s esophagus. Clin Cancer Res. 2000;6:3153–3158
  63. Ireland AP, Clark GWB, DeMeester T. Barrett’s esophagus (The significance of p53 in clinical practice). Ann Surg. 1997;225:17–30
  64. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet. 2002;16:1587–1589
  65. Jenkins GLS, Doak SH, Parry JM, et al.  Genetic pathways involved in the progression of Barrett’s metaplasia to adenocarcinoma. Br J Surg. 2002;89:824–837
  66. Xu Y, Selaru FM, Yin J, et al.  Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett’s esophagus and esophageal cancer. Cancer Res. 2002;62:3493–3497
  67. Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol. 2002;8:586–590
  68. Rosivatz E, Becker I, Specht K, et al.  Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161:1881–1891
  69. Berx G, Becker KF, Hofler H, et al.  Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12:226–237
  70. Tamura G, Yin J, Wang S, et al.  E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92:569–573
  71. Fenoglio-Preiser CM, Wang J, Stemmermann GN, et al.  TP53 and gastric carcinoma (A review). Hum Mutat. 2003;21:258–270
  72. Boussioutas A, Li H, Liu J, et al.  Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 2003;63:2569–2577

PII: S0093-7754(04)00241-6

doi: 10.1053/j.seminoncol.2004.04.020

Seminars in Oncology
Volume 31, Issue 4 , Pages 465-475 , August 2004

Article Tools

* Image Usage & Resolution